Home › Immunoblastic Lymphadenopathy › Michigan
Immunoblastic Lymphadenopathy clinical trials in Michigan
4 studies for Immunoblastic Lymphadenopathy are looking for participants at sites in Michigan.
Cities in Michigan
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Roger Cancer Center University of Michigan Health, Ann Arbor
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06561048A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06393738Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- University of Michigan, Ann Arbor
- Barbara Ann Karmanos Cancer Institute Wayne State University, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2025 · NCT04234048From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.